CNTY-101

N/A

Report date: 2025/05/07 14:45:44

Base Information

Drug NameCNTY-101
Drug Alias NameCNTY-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsNatural killer cell replacementsImmunologic cytotoxicity
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, DiffuseLupus Erythematosus, SystemicLupus Nephritis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCentury Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCentury Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, DiffuseLupus Erythematosus, SystemicLupus Nephritis +[4] 
Inactive IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A